India Biomarker Atlas
The Atlas is a proprietary biomarker database constructed on the Apollo Hospitals biobank substrate. It is referenced across OmicsOS, ClinicalBridge, IVD sprints, and clinical stratification — and licensed to pharma as a standalone data product.
Why it matters
Western genomic references (TCGA, UK Biobank) under-represent India’s ~4,600 population groups. The Atlas is the genomic Rosetta Stone for Asia — a 3–5 year structural lead once Apollo partnership closes.
What the Atlas contains
Multiomics layers
WGS/WES, scRNA-seq, spatial transcriptomics, proteomics, metabolomics — linked to structured clinical phenotype from Apollo EHR.
Longitudinal outcomes
Treatment response, progression, adverse events — enabling response-predictive and safety-predictive biomarker discovery.
India-specific variants
Population-frequency annotations for CYP enzymes, HLA types, and disease-associated variants rare or absent in Western cohorts.
Provenance metadata
Every entry traceable to consent status, collection site, assay method, and quality score — audit-ready for regulatory submission.
Growth trajectory
| Year | Atlas entries | Primary sources |
|---|---|---|
| Year 1 | 5,000 | Apollo oncology + cardiometabolic pilot cohorts; IVD sprint outputs |
| Year 2 | 50,000 | Expanded disease verticals; PV sub-cohort enrichment |
| Year 3 | 500K | Pan-India Apollo network; SEA genomics via BioHelix/GIS collaboration |
| Year 5 | 5M+ | Continuous enrichment from every LabOS closed-loop cycle |
Commercial model
Licensing tiers
- Research license — $200K–500K/yr, academic and early-stage biotech
- Commercial license — $500K–2M/yr, pharma CDx and trial design
- Co-development — equity + royalty on biomarker-derived assets
Apollo economics
25–35% revenue share to Apollo on Atlas licensing. Federated learning ensures raw patient data never leaves Apollo sovereign infrastructure — only differential-privacy outputs and model weights cross the boundary.
Use cases
Companion Dx development · Clinical trial stratification · Drug repositioning · Phase 4 PGx signal baselines · Rare-disease mechanism work where Western references fail.